IFNB1 and myeloid sarcoma: The increased pre-treatment percentages of IL17-producing CD4+T and CD8+T cells in MS patients, especially in MS patients without IFNβ or corticosteroids, are consistent with a previous study showing that peripheral blood Th17 cells increase in Western MS patients [21].